Fortrea Holdings Inc. logo FTRE - Fortrea Holdings Inc.

Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY 0
BUY 5
HOLD 6
SELL 1
STRONG
SELL 0
| PRICE TARGET: $20.00 DETAILS
HIGH: $23.00
LOW: $16.00
MEDIAN: $20.00
CONSENSUS: $20.00
UPSIDE: 9.80%

Stock News

Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials

Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials

Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea's early clinical development network as Worldwide advances its strategy to scale clinical development, therapeutic leadership and high-growth markets Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea's early clinical development network as Worldwide advances its strategy to scale clinical development, therapeutic leadership and high-growth markets

Sep 02, 2026 03:00 AM • globenewswire.com
Fortrea Holdings: The Turnaround Is Showing Up In Earnings Before Revenue

Fortrea Holdings: The Turnaround Is Showing Up In Earnings Before Revenue

Fortrea Holdings Inc. is rated Buy at ~$18.86, driven by an earnings turnaround from aggressive cost reductions, not revenue growth. Adjusted EBITDA rose ~24% in H1 despite a ~3.4% revenue decline, as direct costs and SG&A fell faster than sales. Net new business awards increased ~19% YoY, with a trailing-12-month book-to-bill ratio of 1.12x, but revenue conversion remains uncertain.

Aug 30, 2026 07:14 AM • seekingalpha.com
Kaskela Law Firm Announces Investigation of Fortrea Holdings Inc. (FTRE) and Encourages Long-Term FTRE Shareholders with Investment Losses to Contact the Firm

Kaskela Law Firm Announces Investigation of Fortrea Holdings Inc. (FTRE) and Encourages Long-Term FTRE Shareholders with Investment Losses to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating Fortrea Holdings Inc. (Nasdaq: FTRE) (“Fortrea”) on behalf of the company's long-term investors. Click here for additional information: https://kaskelalaw.com/case/fortrea-holdings/ Recently a securities fraud complaint was filed against Fortrea on behalf of certain investors who purchased shares of the company's stock between July 5, 2023 and February 28, 2025 (the “Wrongdoing Period”). Accor.

Jul 23, 2026 03:00 AM • businesswire.com
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced the granting of an inducement award of restricted stock units (“RSUs”) on June 10, 2026, to 10 newly hired employees. The award consisted of 240,500 RSUs that vest in three equal annual installments starting June 10, 2027, subject to the employee's continuous employment through the applicable vesting date. The RSUs are subject to the terms and conditions of the Company's Amended and Restated 2025 Inducement Award Plan and the award agreements covering the grants. These awards follow Nasdaq Listing Rule 5635(c)(4) and are intended as an inducement material to the individual becoming a new employee of the Company.

Jun 10, 2026 12:15 PM • globenewswire.com
Fortrea to Attend Jefferies Global Healthcare Conference

Fortrea to Attend Jefferies Global Healthcare Conference

DURHAM, N. C. , June 02, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization ("CRO"), today announced that that CEO Anshul Thakral, CFO Jill McConnell, and SVP of Investor Relations, Tracy Krumme will participate in the following conference: Jefferies Global Healthcare Conference (NYC)Date: Thursday, June 4, 2026Time: 8:45 AM EDTFormat: Fireside Chat To register for the live webcast, please click here.

Jun 02, 2026 02:00 PM • globenewswire.com

Price Targets